stockrow
Saturday 7 November 2026
Export ALLO’s income statement to Excel — free account
Allogene Therapeutics, Inc.
ALLO Healthcare Biotechnology
Allogene Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22,000.00, down 76.8% from fiscal 2023.
- Revenue
- +20,990.9%
- EPS
- +43.5%
- Free cash flow
- +17.7%
Quarter to June 2026, against a year earlier
1.04
0.05
−4.59%
Follow ALLO
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 114 | 0 | 0 | 0 | — | 5 | (94.2%) | 4 | 12 | 85 | +370.6% | |
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | — | 100.00 | +100.0 pt | ||||||
| EBT | — | 0 | (212) | (185) | (316) | (182) | (340) | (327) | (257) | (191) | (165) | n/m | ||||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | (159.57) | (218,214.10) | (344,489.47) | (1,168,850.00) | 0.00 | (3,517.41) | 0.0 pt | ||||||
| Net income | — | 0 | (212) | (185) | (316) | (182) | (340) | (327) | (258) | (191) | (165) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.84 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | n/m | |||||
| Earnings | — | — | (7.31) | (1.83) | (2.08) | (1.34) | (2.32) | (2.09) | (1.32) | (0.87) | (0.67) | (26.2%) | ||||||
| Cash flow | — | 0.00 | (1.54) | (1.36) | (0.96) | (1.36) | (1.54) | (1.51) | (1.03) | (0.68) | (0.31) | n/m | ||||||
| Capex | — | 0.00 | (0.18) | (0.50) | (0.55) | (0.16) | (0.04) | (0.01) | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | 0.00 | (1.73) | (1.86) | (1.50) | (1.52) | (1.58) | (1.52) | (1.03) | (0.68) | (0.31) | n/m | ||||||
| Book value | — | 0.00 | 24.29 | 6.22 | 8.97 | 6.81 | 4.66 | 3.26 | 2.17 | 1.33 | 1.33 | n/m | ||||||
| Shares, m | — | 118 | 29 | 101 | 120 | 136 | 143 | 157 | 195 | 221 | 253 | +8.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | 17.76 | 5,285.44 | 5,979.93 | 4,769.53 | — | 72.71 | 4,013.2 | ||||||
| P/B | — | — | — | — | — | 2.19 | 1.24 | 1.11 | 0.98 | — | 0.78 | 1.4 | ||||||
| EV/Sales | — | — | — | — | — | 13.75 | 1,969.28 | 1,256.80 | 1,407.74 | — | 2.02 | 1,161.9 | ||||||
| EV/FCF | — | — | — | — | — | (7.61) | (1.36) | (0.50) | (0.61) | — | (0.09) | (2.5) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | 0 | (45) | (137) | (115) | (185) | (221) | (238) | (200) | (149) | (102) | n/m | |||||
| Capex | — | 0 | (5) | (51) | (66) | (21) | (5) | (2) | (1) | 0 | 0 | n/m | ||||||
| Free cash flow | — | 0 | (50) | (188) | (181) | (206) | (226) | (239) | (201) | (150) | (103) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | 0 | 439 | 511 | 751 | 423 | 475 | 422 | 268 | 225 | 308 | n/m | |||||
| Net debt | — | — | (459) | (531) | (828) | (457) | (517) | (449) | (292) | (250) | (333) | (8.3%) | ||||||
| Shareholders’ equity | — | 0 | 703 | 629 | 1,080 | 925 | 667 | 512 | 422 | 293 | 436 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | 0.00 | (54.66) | (24.75) | (32.52) | (15.98) | (36.36) | (44.70) | (43.24) | (39.58) | (32.43) | (39.6) pt | |||||
| ROIC | — | 0.00 | (49.44) | (128.19) | (64.12) | (24.07) | (140.22) | (322.39) | (131.65) | (309.04) | (108.81) | (309.0) pt | ||||||
| ROE | — | 0.00 | (60.16) | (27.71) | (37.03) | (18.16) | (42.76) | (55.51) | (55.13) | (53.42) | (42.39) | (53.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | 122 | 206 | 265 | 310 | 361 | 233 | 229 | 152 | — | +3.2% | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.37 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2024 · latest quarter Jun 2026
Allogene Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BLSM BlossomHill Therapeutics, Inc. | $392.6M | — (loss-making) | — | — | n/m | — | — | 0.00% | Compare |
| EDIT Editas Medicine, Inc. | $391.6M | — (loss-making) | — (loss-making) | +232.31% (above 0%: growing) | n/m | +40.72% (above 0%: growing) | 100.00% | (156.05%) | Compare |
| ALT Altimmune, Inc. | $383.2M | — (loss-making) | — (loss-making) | +520.00% (above 0%: growing) | n/m | −25.27% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| TECX Tectonic Therapeutic, Inc. | $379.7M | — (loss-making) | — | — | n/m | −46.69% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALLO Allogene Therapeutics, Inc. | $376.6M | — (loss-making) | — (loss-making) | +20,990.91% (above 0%: growing) | n/m | +17.73% (above 0%: growing) | 100.00% | (1,011.21%) | |
| LYEL Lyell Immunopharma, Inc. | $367.6M | — (loss-making) | — (loss-making) | −80.00% (below 0%: shrinking) | n/m | −21.82% (below 0%: shrinking) | 100.00% | (1,609,833.33%) | Compare |
| CCCC C4 Therapeutics, Inc. | $362.9M | — (loss-making) | — (loss-making) | −24.59% (below 0%: shrinking) | n/m | +17.88% (above 0%: growing) | 100.00% | (290.46%) | Compare |
| ZURA Zura Bio Limited | $358.3M | — (loss-making) | — | — | n/m | −26.22% (below 0%: shrinking) | — | 0.00% | Compare |
| TRXB TRex Bio Inc. | $356.5M | — | — | — | — | — | — | — | Compare |
| Median of peers | $373.6M | — | — | +103.86% | — | −23.54% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 30 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 6.14m | 1.93m | 21.78 |
| 2024 | 4.48m | 872.37k | 33.86 |
| 2023 | 14.06m | 1.29m | 51.03 |
Ownership
Directors and executive officers, together
13.20%
Pfizer Inc.
9.00%
TPG GP A, LLC
7.60%
Citadel Multi-Strategy Equities Master Fund Ltd.
5.50%
Arie Belldegrun, M.D.
5.40%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement